Skip to main content Skip to main navigation menu Skip to site footer
Page Header Logo
  • ABOUT THE JOURNAL
    • Focus and scope
    • Editorial Management Process
  • EDITORIAL POLICY
    • Ethical Publication Standards
    • Open Access Policy
    • Anti-plagiarism Policy
    • Copyright
    • Policy for Journal Archiving
    • Claim Policy
  • AUTHORS
    • Guidelines to Authors
    • Sending and Receiving Papers
    • Structure and Content of Articles
    • Article Evaluation Process
    • ORCID
    • coi_disclosure Colombia Médica ICMJE
    • Copyright Transfer Statement Colombia Médica
  • PEER REVIEW
    • Peer Review Process
    • Evaluation Forms
  • EDITORIAL TEAM
    • Editorial team
    • Contact
  • ARTICLES
    • Current
    • Archives
  • COLLECTIONS
Search
  • Register
  • Login
  1. Home /
  2. Archives /
  3. Vol 39 No 4 (2008) /
  4. Original Articles

Imatinib treatment and pharmacogenotype CYP3A4 in relation with the clonal expansion Ph(+) in chronic myeloid leukemia (CML).

  • Abstract
  • Keywords
  • Author Biography

Abstract

Introduction: Imatinib is an inhibitor of the BCR-ABL tyrosine-kinase that has dramatically changed the treatment of patient with Chronic myeloid leukemia (CML) positive for the Philadelphia chromosome (Ph+). This compound is mainly metabolized by the cytochrome CYP3A4 enzyme, coded by a gene with individual variations that could interfere with the effectiveness of the treatment, due to the fact that particular single nucleotide polymorphisms (SNPs), i.e., CYP3A4*1B y CYP3A4*2, have shown to exert a significant influence on the metabolic activity of this pharmacologically important enzyme.
Objective: Evaluate the frequency of pharmacogenetically important polymorphisms in the CYP3A4 gen in a Colombian population of patients with CML being treated with this novel drug (Imatinib), in parallel with a control population of 164 healthy individuals. Correlate the evolution of the clonal expansion Ph(+) with the presence of these SNPs and the length of treatment.
Methodology: PCR-RFLP genotyping for the CYP3A4* 1B y CYP3A4*2 SNPs. RBHG replication banding for the evaluation of the presence of the Ph(+) markers in spontaneous mitotic blasts.
Results: A positive cytogenetic response and/or correlation was detected between the length of the imatinib treatment and a reduction in the percentage of Ph(+) blasts. Genotyping indicate that CYP3A4*1B polymorphism does no affect the cytogenetic response in imatinib treated Ph(+) patients, and that the pharmacorelevant CYP3A4*2 SNP is not present in this population of patients and controls (N=194).
Conclusions: The pharmacogenotype CYP3A4*2 (exon 7) does not affect the induced positive cytogenetic response triggered by the imatinib treatment, that generally induces a reduction in Ph(+) blasts en relation with the duration of the treatment.

Authors

  • Mauricio Camargo Universidad de Antioquia
  • María Isabel Soto Marín Universidad de Antioquia.
  • Olga Zea Universidad de Antioquia
  • Domingo Saavedra Clínica Vida

Downloads

Download data is not yet available.

Keywords

  • Imatinib
  • Chronic myeloid leucemia
  • CML
  • CYP3A4
  • Philadelphia chromosome
  • Pharmacogenetics
  • SNPs

Author Biography


, Universidad de Antioquia.
Grupo de Genética de Poblaciones y Mutacarcinogénesis, Sede de Investigación Universitaria (SIU), Universidad de Antioquia, Medellín, Colombia.
  • PDF
  • HTML
Submitted
2009-12-02
| 618 |
How to Cite
Camargo, M., Soto Marín, M. I., Zea, O., & Saavedra, D. (1). Imatinib treatment and pharmacogenotype CYP3A4 in relation with the clonal expansion Ph(+) in chronic myeloid leukemia (CML). Colombia Médica, 39(4), 314-322. https://doi.org/10.25100/cm.v39i4.613
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
Issue
Vol 39 No 4 (2008)
Section
Original Articles

The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use

Online ISSN: 1657-9534
Make a Submission

Bibliographics database

Full-text database

Citation Index

Bibliographical information system

Memberships

Licencia Creative Commons
This work is under License Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) .

Indexed

.
0.82
2018CiteScore
 
 
68th percentile
Powered by  Scopus
.
Information
  • For Authors
Universidad del Valle
Universidad del Valle
  • Cali - Colombia
  • © 1994 - 2020
Dirección:
  • Ciudad Universitaria Meléndez
  • Calle 13 # 100-00
  •  
  • Sede San Fernando
  • Calle 4B N° 36-00
PBX:
  • +57 2 3212100
  • Línea gratuita: 018000 22 00 21
  • A.A.25360
Redes Sociales:

2020 Universidad del Valle - Vigilada MinEducación

//Go to www.addthis.com/dashboard to customize your tools